AstraZeneca pauses coronavirus vaccine trial, what does this mean for markets?

Ross J Burland FXStreet

It was earlier reported that the AstraZeneca Covid-19 vaccine trial was on hold over safety concern.

See here AstraZeneca Covid-19 vaccine trial on hold over safety concern – STAT News

To elaborate, discussions about early authorizations and reports about White House pressure to speed along a coronavirus vaccine have worried the public.

The latest reports that Drug giant AstraZeneca said Tuesday it had paused global trials of its coronavirus vaccine because of unexplained illness in one of the volunteers is a real spanner in the works for risk appetite.

Further information

The company is testing its vaccine, called the Oxford vaccine which markets had high hopes for.

However, the hold up vs the concerns about moving too fast is a cocktail of contradictions which is concerning on both sides of the coin.

Earlier Tuesday, AstraZeneca joined eight other companies in signing a pledge promising they would not seek premature government approval for any coronavirus vaccine which could help to alleviate concerns to an extent.

"We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles," a statement read that was signed by the CEOs of AstraZeneca, BioNTech GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi.

"We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved," they added.

Nevertheless, with the stock market in a rout and risk assets struggling, this vaccine news is another problematic area for markets to recover from and we are indeed seeing downside in Asia today.

Market update since the news

The Nikkei is down some 1.5%.

Australian stocks that had kicked off Wednesday in the negative zone, pulled down by the US equities, is now down over 2%.

The Hang Seng Index is down over 1% and the SSE Composite is down over 1% also.

Author

Ross J Burland

FXStreet

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

AUD/USD sits at three-week highs above 0.7000 on hawkish RBA-speak

AUD/USD holds a positive bias for the fourth straight day, trading above 0.7000 in the Asian session on Wednesday and at three-week highs. RBA Deputy Governor Andrew Hauser's hawkish remarks and inflation concerns underpin the pair. However, the upside appears capped as the US Dollar attracts some buyers amid looming US-Iran uncertainty.

USD/JPY remains confined in a familiar range below 158.50

USD/JPY sees some dip-buying in the Asian session on Wednesday, though it remains confined within a multi-week range near 158.50 as the uncertainty over the timing of the next BoJ rate hike keeps Japanese Yen bulls on the defensive. Meanwhile, hawkish Fed expectations, bolstered by inflation risks stemming from volatile oil prices, underpin the US Dollar. However, looming intervention fears could limit JPY losses and cap the currency pair.

Gold advances modestly; targets $4,150

Gold prices manage to reverse three consecutive daily declines, trading just below the $4,150 mark per troy ounce on Wednesday. The precious metal’s recovery comes amid a slight drop in the US Dollar, mixed US Treasury yields across the board and a widespread cautious tone from the US-Iran front.

Bitcoin eyes a break above $85,000 as institutional demand returns

Bitcoin edges higher above $83,000, extending its rebound from the 50-day EMA near $80,786. US-listed BTC spot ETFs recorded over $23 million in net inflows on Tuesday, following Monday's $526 million, signaling a return of institutional demand.

What November 3 means for the Fed's rate path and the US Dollar

The USD faces a decisive period ahead of the November 3 midterm elections. While markets anticipate another interest rate increase from the Fed in December, the battle for control of Congress could reshape fiscal policy expectations and, indirectly, the path of US monetary policy in 2027.

The US Dollar fell. Gold didn't rally. That tells you everything

Gold (XAU/USD) is struggling to capitalize on a weaker US Dollar (USD), after repeatedly failing to establish itself above the $4,200 level. The precious metal remains confined to a relatively narrow trading range despite a combination of developments that would normally support higher prices.